Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$195.31 USD

195.31
1,866,244

-1.51 (-0.77%)

Updated Oct 3, 2024 02:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus

J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.

Kinjel Shah headshot

3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement

Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.

AC Immune Initiates Phase I Study for Alzheimer's Disease

AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.

Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance

Novartis (NVS) beats sales estimates in the second quarter, driven by robust performance of key drugs and biosimilars.

Should Value Investors Buy AbbVie (ABBV) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know

AbbVie (ABBV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AbbVie (ABBV) is an Incredible Growth Stock: 3 Reasons Why

AbbVie (ABBV) is well positioned to outperform the market, as it exhibits above-average growth in financials.

AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio

AbbVie (ABBV) buys Mavupharma to develop novel treatments for cancer using the latter's STING signaling pathway.

J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View

J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

AbbVie (ABBV) closed at $70.29 in the latest trading session, marking a +0.01% move from the prior day.

FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug

The FDA accepts Neurocrine's (NBIX) NDA for opicapone, developed as an adjunctive treatment to levodopa/carbidopa for patients with Parkinson's disease, who currently experience OFF episodes.

J&J (JNJ) to Kick-Start Pharma Q2 Earnings: A Beat in Store?

J&J's (JNJ) cancer drugs should continue to perform well in second-quarter 2019. Generic/biosimilar headwinds will hurt Pharma unit's sales.

Nilanjan Banerjee headshot

Will Patent Woes Boost Pharma Stock Megamergers Further?

With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

AbbVie (ABBV) closed at $71.25 in the latest trading session, marking a +0.04% move from the prior day.

ObsEva Ends Recruitment in Second Uterine Fibroids Study

ObsEva (OBSV) completes patient recruitment in the second pivotal phase III study evaluating linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids.

The Zacks Analyst Blog Highlights: Amazon, UnitedHealth, AbbVie, Simon Property and Autodesk

The Zacks Analyst Blog Highlights: Amazon, UnitedHealth, AbbVie, Simon Property and Autodesk

AbbVie (ABBV) Shares Down So Far This Year: Here's Why

AbbVie's (ABBV) stock suffers a poor run on the bourses due to pipeline setbacks, Humira sales erosion in EU and its proposed offer to buy Allergan.

Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Mark Vickery headshot

Top Stock Reports for Amazon, UnitedHealth & AbbVie

Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), UnitedHealth (UNH) and AbbVie (ABBV).

Kinjel Shah headshot

Will the Pharma Space Witness More Mega-Merger Deals in 2H?

After two mega-mergers, Bristol-Myers/Celgene and AbbVie/Allergan, in first half of 2019, it remains to be seen if more such deals are in store for the second half.

Gilead to Submit NDA for Inflammation Drug Filgotinib in '19

Gilead (GILD) is planning to submit regulatory application to the FDA seeking approval for filgotinib as a treatment for rheumatoid arthritis.

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

AbbVie (ABBV) closed at $73.40 in the latest trading session, marking a +0.94% move from the prior day.

Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval

Pfizer (PFE) gets FDA approval for biosimilar Avastin, Zirabev. This is Pfizer's second oncology biosimilar to be approved in United States.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger

AbbVie (ABBV) announces definitive deal to buy Allergan (AGN). Bristol-Myers (BMY) set to sell Celgene's Otezla to complete the impending merger.

Sejuti Banerjea headshot

Is Allergan a Good Deal for AbbVie?

AbbVie is dishing out $63 billion in stock and cash for Allergan, provided it gets regulatory approval.